Airmony is a new sleep apnea device. Portable, light and tubeless, Airmony pushes a continuous flow of air to help sleep apnea patients breathe and enjoy a good night’s sleep. It includes sensors for e-health tech, allowing patients and their doctors to monitor sleep patterns.
Obstructive Sleep Apnea (OSAS) is a common sleep disorder where breathing stops for a few seconds during sleep. It affects up to 6% of the world’s adult population; mostly men, but also women, children and even athletes. Untreated, moderate to severe OSAS can lead to serious health complications, such as heart disease, stroke, diabetes, cancer and depression.
Continuous Positive Airway Pressure (CPAP) devices exist to treat this condition, but our research suggests that 98% are clunky, intrusive, table top versions. Airmony is a new CPAP device – it’s smaller, lighter, tubeless, washable and can be used both by children and adults.
With its low noise level, Airmony is discreet but effective and it runs for more than two nights on a USB rechargeable battery. It also includes sensors for e-health monitoring, allowing both patients and their doctor to review sleep patterns.
Airmony’s development is supported by numerous institutions, including the Estivill Sleep Foundation, founded by renowned sleep specialist, Dr. Eduard Estivill.
We aim to operate with a hybrid model, through distributors and online direct sales, alongside our app, which is currently in development. The sleep apnea devices market is growing at a CAGR of 7.8%, and the total addressable market is projected to be worth $6.49bn by 2023.